Project Grant R01CA293229
Award Date
9/1/24
Completion Date
8/31/29
Dollars Obligated
$707K
Federal Agency
National Cancer Institute
Federal Grant Program
93.393
Assistance Type
Project Grant
Place of Performance
Seattle, WA 98101, USA
Similar Awards
The National Cancer Institute (NCI) awarded a $757,913 Project Grant under the Cancer Cause and Prevention Research program (CFDA 93.393) to the Fred Hutchinson Cancer Center (doing business as Seattle Cancer Care Alliance) for a 5-year period beginning on February 1, 2025. The grant will fund a randomized controlled trial to determine whether providing a smoking cessation smartphone app (iCanQuit) combined with free nicotine replacement therapy (NRT) is more effective and cost-effective at...
This Project Grant award from the National Cancer Institute (NCI), under the Cancer Cause and Prevention Research (CFDA 93.393) program, supports the development and evaluation of a wearable device called "Smokemon" and associated software platform "SmokeDash" to remotely monitor smoking behavior and triggers among cancer survivors. The total award amount is $399,891, with a project period from April 15, 2025 to March 31, 2026. The key products and services to be delivered...
The National Cancer Institute (NCI) awarded a $257,415 Project Grant under the Cancer Cause and Prevention Research (CFDA 93.393) program to The Research Foundation for the State University of New York (RF SUNY) to develop an AI-enhanced smartphone app-based intervention for adolescent e-cigarette cessation. The goal is to create a scalable, cost-effective intervention that uses AI-assisted user profiling and personalized content to help adolescents quit e-cigarettes. The 3-year project will...
The National Cancer Institute (NCI) awarded a $316,873 Project Grant (CFDA 93.393 - Cancer Cause and Prevention Research) to the H. Lee Moffitt Cancer Center and Research Institute Hospital, Inc. in Tampa, Florida. The grant, titled "LIBRE DEL CIGARRILLO: DEVELOPMENT OF AN MHEALTH SMOKING CESSATION APP TO EXTEND REACH OF A VALIDATED SMOKING CESSATION INTERVENTION FOR SPANISH-SPEAKING SMOKERS", aims to adapt a previously validated printed smoking cessation intervention for...
The National Cancer Institute (NCI) awarded a Project Grant under the Cancer Cause and Prevention Research program (CFDA 93.393) to the University of Oklahoma Health Sciences Center to conduct a randomized factorial trial on smoking cessation interventions. The $625,201 award, effective January 1, 2025 through December 31, 2029, will evaluate the combined impact of varenicline medication plus nicotine lozenges, and a smartphone-based medication adherence intervention, on 7-day point prevalence...
This Project Grant award from the National Cancer Institute (CFDA 93.393 - Cancer Cause and Prevention Research) will fund a randomized controlled trial to examine the efficacy of a smartphone app called "Kick-Nic!" for e-cigarette cessation among 306 high school adolescents. The app provides an engaging, multimedia-rich, and interactive cognitive-behavioral therapy platform to help adolescents develop coping skills for e-cigarette-specific triggers and support their cessation efforts....
This federal Project Grant award of $619,175 from the National Cancer Institute (CFDA 93.393 - Cancer Cause and Prevention Research) supports a Type 1 hybrid effectiveness-implementation trial to evaluate a novel harm reduction approach for oncology outpatients who smoke but refuse traditional tobacco treatment. The study will directly compare rates of switching from cigarettes to e-cigarettes against standard care, while also assessing key barriers and facilitators to implementation. The...
This $279,573 federal Project Grant award from the National Cancer Institute (NCI) under the Cancer Cause and Prevention Research program (CFDA 93.393) aims to refine and test a novel biobehavioral smoking cessation intervention that integrates the strategic application of olfactory stimulation (OS) to reduce cigarette craving. The project will be conducted in two phases: Phase I will involve a crossover, micro-randomized controlled trial with 32 treatment-seeking smokers to refine the design...
The National Cancer Institute (NCI) awarded a $1,698,536 Project Grant (CFDA 93.393 - Cancer Cause and Prevention Research) to The General Hospital Corporation, doing business as Massachusetts General Hospital (MGH), to develop and test a remote, young adult lay-counselor delivered behavioral and digital intervention called "QuitVaping" to promote nicotine vaping cessation and prevent escalation of tobacco use among youth aged 14-18. The project will enroll 300 adolescents who vape...
This federal Project Grant award from the National Cancer Institute (CFDA 93.393 - Cancer Cause and Prevention Research) provides $1,319,898 to adapt and test a smoking cessation intervention tailored for transgender and gender-diverse (TGD) individuals. The project aims to explore how gender minority stressors and associated anxiety/depression impact smoking cessation for TGD people, adapt an existing smoking cessation program to address their unique needs, and evaluate the feasibility and...